|Day Low/High||59.51 / 60.49|
|52 Wk Low/High||46.48 / 61.34|
I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.
BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.
Vaccines are on the move (a big plus) even as members of Congress continue to dawdle on a fiscal support package (a big minus).
Plus, stay nimble as the road just ahead could become a bit more treacherous than many may think.
The RMPIA also tops other indexes for year, shooting ahead 29%.
Governments around the world have committed to buying hundreds of millions of doses of AZD1222.
The battle to gain control over Covid-19 is entering a crucial stage and calls for continued determination.
All in all stick with the tipping pointers, they are the drivers of this and the next leg higher.
Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.
I will come back to these names over and over again as we are now in the sweet spot for many.
A lot has happened over the past couple weeks, but little has changed. Let's dig in.
None of these questions have been answered which is why I see chaos ahead as we can't even imagine this process working.
Basically, I think we laid out enough reasons for financial markets to revolt, yet they did not.
The stock market in the Philippines has surged by one-fifth in just over a month amid reasons for optimism.
A look at the charts of Advanced Micro Devices and Tesla, plus a review of the 'broadening' market action from Thursday.
Technical analysis has become so much more accurate a trading tool than it ever was before.
One of the most-hated sectors of the market is taking off, and it's not too late to get on board.
The most important market takeaway right now is that both the Nasdaq Composite and S&P 500 have filled their respective gaps and retaken their 50-day simple moving averages.
Markets have certainly recovered nicely off of the lows of late September. Now, here in mid-October, it feels like it did that cold night back in 1980-something. The wolves are visible and noisy.
Investors are chasing every name that's developing a promising coronavirus vaccine. These stocks will be winners no matter which companies are successful.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
Now, that we have confirmation from the Nasdaq Composite, I think we can say equity markets are indeed back in what I would consider an uptrend.
Even more important than fiscal support moving forward would be the concept of Covid-19 very soon being effectively treatable for the public.
The result has been a technical breakdown in risk-asset pricing -- and the main culprit is without a doubt, the inability of Congress to compromise.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Make sure that your portfolio is composed of sane assets for the balance of this crazy year.
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
The prices of hotels and even beaten up retailers say that many believe a vaccine is on the way -- here's how I would get positioned.
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Also, several scheduled events this week, election risk, earnings to watch.